IGF-1 LR3
Also known as: Long R3 IGF-1, LR3 IGF-1, LR3-IGF-1, Long R3 Insulin-Like Growth Factor 1, Long arginine 3 IGF-1, LR3-IGF-I, IGF-1 Long R3, IGF1-LR3, LONG R3 IGF-I
IGF-1 analogue / Insulin-like growth factor analogue
What it is
IGF-1 LR3 is a modified form of IGF-1 used by bodybuilders for muscle growth, as it stays active in the bloodstream longer than natural IGF-1. Research in animals covers cardiac growth, nerve regeneration, and Alzheimer's models. Not approved for human use; likely WADA-prohibited; evidence mostly from animal studies.
The scientific side
IGF-1 LR3 is a synthetic analogue of insulin-like growth factor-1 (IGF-1) that carries a substitution of arginine at position 3 and an N-terminal 13-amino-acid extension. Its defining pharmacological characteristic is markedly reduced affinity for IGF-binding proteins (IGFBPs) compared with native IGF-1, while retaining high affinity for the IGF-1 receptor (IGF-1R) (PMID 42395176; PMID 36091374; PMID 7683875). Because IGFBPs normally sequester IGF-1 and limit its bioavailability, LR3's low IGFBP affinity results in greater free-ligand availability and prolonged receptor signalling. Receptor binding activates downstream pathways including ERK and PI3K, and stimulates ERK1/2 phosphorylation in an N-glycosylation-dependent manner via IGF-1R. Downstream effects documented in research models include stimulation of cell proliferation, organ and skeletal muscle growth, myoblast proliferation, cardiomyocyte proliferation, and modulation of insulin secretion (PMID 33427051; PMID 19633297; PMID 12947030; PMID 33938236). LR3-IGF-1 is cleared more rapidly from wound fluid than native IGF-1 (half-life approximately 563 min in that model vs. 872 min for IGF-1), consistent with its reduced IGFBP association. LR3 does not bind IGFBP-3 or IGFBP-4, which distinguishes its pharmacology from native IGF-1 (PMID 8691093; PMID 11181549).
Class: IGF-1 analogue / Insulin-like growth factor analogue
Administration & storage
- Administration
- Intravenous infusion via surgically implanted fetal catheter (PMID: 33427051PMID: 39679943PMID: 33938236PMID: 37114757)Mini-osmotic pump / continuous subcutaneous infusion (PMID: 7683875PMID: 8053901PMID: 12067429)Subcutaneous injection (PMID: 18577570)Intranasal administration (PMID: 39610283)Local implant via hydrogel muscle void filler (PMID: 41418663)Serosal application to isolated tissue (in vitroPMID: 22227200)In vitro culture medium supplementation (multiple abstracts)
- Storage
- No storage conditions for IGF-1 LR3 are described in any of the reviewed abstracts. One abstract characterises physicochemical properties of LR3-IGF1 protein inclusion bodies (isoelectric point, electrophoretic mobility) relevant to manufacturing recovery processes, but not to end-user storage.
- Cautions
- No published human clinical trials or human pharmacokinetic/pharmacodynamic data for IGF-1 LR3 were identified in the reviewed abstracts; all dosing and safety data derive from animal and in vitro studies.,IGF-1 LR3 infusion in fetal sheep produced an intrinsic pancreatic islet defect with reduced glucose-stimulated insulin secretion and lower plasma insulin and glucose concentrations, raising concern for dysglycaemia.,LR3 IGF-I treatment was associated with accelerated tumour growth in a cancer cachexia mouse model, suggesting potential mitogenic risk in the context of pre-existing malignancy.,In tumour-bearing rats, LR3-IGF-I infusion decreased food intake, lowered insulin and glucose, and did not improve muscle protein accretion, raising concern about metabolic substrate depletion in catabolic states.,IGF-1 LR3 is classified in one narrative review among unregulated peptides lacking regulatory approval for performance or physique indications, with uncertainty around product composition, dose accuracy, and stacking practices in unregulated supply chains.,Sterile technique is essential for any injectable compound to prevent infection — this is a universal caution not specific to IGF-1 LR3.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. One review notes absence of regulatory approval for physique- or performance-related indications and classifies IGF-1 LR3 among unregulated peptides…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Fetal growth and organ development (animal model) Animal studies only
- 1-week intravenous infusion of LR3 IGF-1 into late-gestation fetal sheep increased weight of heart, adrenal gland, and spleen, and increased skeletal muscle myoblast proliferation, without significantly increasing total fetal weight or placental nutrient transfer rates. PMID 33427051 Stremming et al., Am J Physiol Endocrinol Metab (2021)
- 1-week IGF-1 LR3 infusion into growth-restricted (FGR) fetal sheep did not improve fetal body weight, insulin, glucose, oxygen, or glucose-stimulated insulin secretion, but did reduce circulating amino acid concentrations. PMID 39679943 White et al., Am J Physiol Endocrinol Metab (2025)
- Human recombinant LR3 IGF-1 infused into late-gestation fetal sheep increased fetal organ growth and skeletal muscle myoblast proliferation; a species-specific recombinant sheep IGF-1 was subsequently developed to better model physiological IGFBP regulation. PMID 36091374 Stremming et al., Front Physiol (2022)
- Attenuation of glucose-stimulated insulin secretion in fetal sheep (animal model) Animal studies only
- 1-week infusion of IGF-1 LR3 into late-gestation fetal sheep lowered plasma insulin and glucose concentrations and reduced fetal glucose-stimulated insulin secretion; impaired secretion persisted in isolated islets, indicating an intrinsic islet defect. PMID 33938236 White et al., Am J Physiol Endocrinol Metab (2021)
- A 90-min acute infusion of IGF-1 LR3 suppressed fetal plasma insulin and in-vivo glucose-stimulated insulin secretion, but insulin secretion from isolated islets was not different, suggesting the acute effect on beta cells is reversible. PMID 37114757 White et al., J Dev Orig Health Dis (2023)
- Cardiac growth and cardiomyocyte proliferation (animal model) Animal studies only
- In-vivo LR3 IGF-1 administration to near-term fetal sheep decreased the percentage of binucleated cardiomyocytes; in culture, LR3 IGF-1 increased cardiomyocyte BrdU uptake 3–5-fold via ERK and PI3K signalling. PMID 12947030 Sundgren et al., Am J Physiol Regul Integr Comp Physiol (2003)
- IGF-1 LR3 treatment in near-term fetal sheep increased cardiac mass; coronary conductance was preserved per gram of tissue, indicating coordinated coronary vascular growth accompanying myocardial growth. PMID 32573852 Jonker et al., FASEB J (2020)
- Peripheral nerve regeneration (animal model) Animal studies only
- A decellularized plant-based nerve conduit with controlled release of IGF-1 LR3 significantly improved axonal regeneration in a rat sciatic nerve defect model, with performance comparable to autologous nerve grafts and without inducing systemic toxicity. PMID 41015370 Yavuz et al., Int J Biol Macromol (2025)
- Volumetric muscle loss repair (animal model) Animal studies only
- High-dose PLGA-encapsulated IGF-1 LR3 (280 µg) delivered via a synthetic hydrogel muscle void filler increased muscle weight compared to control at 28 days post-implantation in a rat VML model, but did not improve specific torque, maximum torque, fibrosis, fiber size, or fiber count. PMID 41418663 Clark et al., J Surg Res (2026)
- Alzheimer's disease / amyloid pathology (animal model) Animal studies only
- Intranasal LR3-IGF-1 treatment for 7 months in male 5XFAD mice improved body composition and reduced filamentous amyloid plaques in cortex, but did not significantly preserve cognitive function. In vitro, LR3-IGF-1 enhanced Aβ1-42 uptake by BV2 microglial cells. PMID 39610283 Engel et al., J Alzheimers Dis (2025)
- Cancer cachexia / muscle wasting (animal and in vitro model) Animal studies only
- LR3 IGF-1 limited loss of muscle mass in a C26 tumour-bearing mouse cachexia model in vivo, and increased differentiation index and mean nuclei count in C2C12 cells in vitro. However, LR3 IGF-1 treatment was associated with accelerated tumour growth in vivo. PMID 31285507 Levolger et al., Sci Rep (2019)
- Tumour-bearing rat metabolism and muscle protein accretion (animal model) Animal studies only
- In mammary adenocarcinoma-bearing rats, infusion of LR3-IGF-I significantly decreased food intake, lowered circulating insulin and glucose, decreased muscle protein synthesis and increased muscle protein breakdown; tumour growth was increased by LR3-IGF-I. Combined insulin + LR3-IGF-I produced synergistic increases in PMID 8053901 Tomas et al., Biochem J (1994)
- Restoration of growth in diabetic rats (animal model) Animal studies only
- In streptozotocin-diabetic rats, LR3-IGF-1 was 2.5–3 times more potent than native IGF-1 in restoring growth and nitrogen balance when infused via mini-osmotic pumps. LR3-IGF-1 did not restore insulin-dependent metabolic processes (e.g., glucosuria, N-methylhistidine excretion) unlike insulin. PMID 7683875 Tomas et al., Biochem J (1993)
- Growth promotion in neonatal pigs (animal model) Animal studies only
- In artificially reared neonatal pigs infused at 2–16 µg/h, LR3IGF-I increased daily weight gain (457 vs. 386 g/d) and milk intake during the second 9 days of a higher-dose phase, and decreased plasma IGF-I concentrations. Effects were more pronounced than with native IGF-I at equivalent doses. PMID 12067429 Dunshea et al., Br J Nutr (2002)
- Lactation enhancement in mice (animal model) Animal studies only
- Subcutaneous injections of long-R3-IGF-I (LR3) modestly increased lactation capacity in mice during prolonged lactation and increased mammary phospho-Akt and SOCS3 gene expression. PMID 18577570 Hadsell et al., J Endocrinol (2008)
- Small intestinal cell growth (animal model) Animal studies only
- LR3-IGF-I administered by osmotic pump affected small intestinal mucosal cellularity similarly to IGF-I but with higher potency in animal studies reviewed. PMID 10226789 MacDonald, Horm Metab Res (1999)
- Rumen epithelial sodium transport (animal/in vitro model) In vitro only
- At 20–100 µg/L, serosal application of LR3-IGF-1 increased mucosal-to-serosal and net Na+ flux across isolated sheep rumen epithelium by approximately 60% within 30 min, mediated by Na+-H+ exchange activity. PMID 22227200 Shen et al., Exp Physiol (2012)
- IGF-1 receptor signalling studies / research tool use In vitro only
- IGF-1 LR3 was used as an IGF-1R ligand in CHO cell studies; N-glycosylation mutants showed reduced ERK1/2 phosphorylation upon IGF-1 LR3 stimulation, demonstrating the requirement for proper glycosylation in IGF-1R signalling. PMID 36499281 Salvi et al., Int J Mol Sci (2022)
- LR3-IGF-I (not bound by IGFBP-3) was used to demonstrate that IGFBP-3 potentiation of IGF-1R signalling in MCF-10A breast epithelial cells requires sphingosine kinase-1 activity. PMID 19633297 Martin et al., J Biol Chem (2009)
- Ovarian follicle and granulosa/theca cell research (in vitro and animal model) Mixed
- LR3 IGF-I increased bovine preantral follicle diameter and estradiol production in a dose-dependent manner in vitro, but high concentrations produced smaller oocyte/follicle ratios and increased oocyte degeneration. PMID 17636166 Thomas et al., Reproduction (2007)
- In-vivo infusion of LR3-IGFI into rats differentially affected cumulus oophorus vs. mural granulosa cell proliferation; differential responses were observed upon subsequent in-vitro FSH/LH exposure. PMID 11334915 Khamsi & Roberge, Fertil Steril (2001)
Safety signals
- Attenuation of glucose-stimulated insulin secretion (intrinsic islet defect) following 1-week infusion in fetal sheep; lower plasma insulin and glucose concentrations observed. PMID 33938236
- Reduced fetal circulating amino acid concentrations following 1-week LR3 IGF-1 infusion in growth-restricted fetal sheep, potentially reflecting altered substrate availability. PMID 39679943
- Accelerated tumour growth in C26 tumour-bearing mice treated with LR3 IGF-I, despite limiting loss of muscle mass. PMID 31285507
- Decreased food intake, reduced circulating insulin and glucose, and increased tumour growth in mammary adenocarcinoma-bearing rats infused with LR3-IGF-I. PMID 8053901
- Oocyte degeneration and reduced oocyte/follicle ratio observed with high concentrations of LR3 IGF-I in bovine preantral follicle culture, suggesting potential reproductive tissue toxicity at supraphysiological concentrations. PMID 17636166
- Adverse effects of GH-IGF-1 axis peptides in self-administration contexts reported in a narrative review to include endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms, and injection-site reactions. IGF-1 LR3 is listed among the implicated agents. PMID 42395176
- LR3-IGF-I did not restore glucosuria or muscle protein breakdown markers to normal in diabetic rats at high doses, indicating incomplete replication of insulin's metabolic effects despite growth restoration. PMID 7683875
Contraindications
- Potential concern in individuals with active malignancy: LR3 IGF-I accelerated tumour growth in a mouse cancer cachexia model despite limiting muscle wasting. PMID 31285507
- Potential concern regarding use in conditions of placental insufficiency or fetal growth restriction: IGF-1 LR3 did not improve growth outcomes and reduced circulating amino acids in FGR fetal sheep. PMID 39679943
Protocol
50-100 mcg subcutaneous injection, once daily. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous infusion | LR3 IGF-1 intravenous infusion (exact dose rate not specified in abstract; described as 1-week infusion) | 1 week | animal | Research PMID 33427051 |
| Intravenous infusion (directly into fetal circulation via catheter) | 1.17 ± 0.12 µg·kg⁻¹·h⁻¹ (LR3 group); previously tested at 6.6 µg·kg⁻¹·h⁻¹ in normal fetal sheep (referenced from prior study) | 1 week | animal | Research PMID 39679943 |
| Intravenous infusion into fetal sheep | 90-minute infusion (dose rate not specified in abstract) | 90 minutes | animal | Research PMID 37114757 |
| Intravenous infusion | IGF-1 LR3 infusion for 1 week (dose rate not specified in abstract) | 1 week | animal | Research PMID 33938236 |
| Implanted hydrogel (intramuscular/local) | Low dose: 28 µg; High dose: 280 µg (soluble or PLGA-encapsulated, delivered via hydrogel muscle void filler) | 28 days (assessed at 28 days post-implantation) | animal | Research PMID 41418663 |
| Intranasal | Intranasal LR3-IGF-1 (dose not specified in abstract) | 7 months (3–10 months of age) | animal | Research PMID 39610283 |
| Intraperitoneal (based on study design; oral noted for GW788388 comparator) | LR3 IGF-I (dose not specified in abstract) | Not specified in abstract | animal | Research PMID 31285507 |
| Osmotic minipump infusion | 200 or 500 µg/day (IGFs including LR3-IGF-I) | 6–7 days | animal | Research PMID 8053901 |
| Mini-osmotic pump infusion | Graded doses up to 695 µg/day (IGF-I); LR3-IGF-I described as 2.5–3 times more potent | 7 days | animal | Research PMID 7683875 |
| Continuous infusion (osmotic pump) | 2, 4, or 8 µg/h (Experiment 1); 8 µg/h escalating to 16 µg/h (Experiment 2) | 8 days (Experiment 1); 9 + 9 days (Experiment 2) | animal | Research PMID 12067429 |
| Subcutaneous injection | LR3 administered as subcutaneous injections (dose not specified in abstract) | Prolonged lactation period (duration not specified in abstract) | animal | Research PMID 18577570 |
| Serosal application to isolated rumen epithelium (in vitro) | 20–100 µg/L (serosal application) | Acute (within 30 min of application) | in_vitro | Research PMID 22227200 |
| In vivo infusion (pump) | LR3-IGFI infusion in vivo (dose not specified in abstract) | 24–29 days of age (5 days) | animal | Research PMID 11334915 |
| In vivo infusion (pump), then in vitro culture | LR3-IGF-I (dose not specified in abstract) | Not specified in abstract | animal | Research PMID 11524236 |
| In vivo infusion (pump) | LR3-IGF-I (dose not specified in abstract) | Not specified in abstract | animal | Research PMID 10855689 |
| In vitro culture medium supplementation | 100 ng/ml | In vitro embryo culture period (not specified) | in_vitro | Research PMID 11181549 |
| In vitro culture medium supplementation | Increasing doses including up to 1000 ng/ml | 6 days | in_vitro | Research PMID 17636166 |
| Injection (route not specified in abstract) | LR3-IGF-I injection (dose not specified in abstract) | Single injection (acute) | animal | Research PMID 16166219 |
| In vitro culture medium supplementation | LR3-IGF-I at 1–100 µg/L (analogue in serum-free culture) | Up to 8 days | in_vitro | Research PMID 26166219 |
| In vitro culture medium supplementation | 1–100 µg/L LR3-IGF-I | Up to 144 hours | in_vitro | Research PMID 9538331 |
| In vitro culture medium supplementation | 100 ng/ml LR3-IGF-1 | 24 hours | in_vitro | Research PMID 25154301 |
| subcutaneous injection | 50-100 mcg | once daily · 4-6 weeks | bodybuilders and performance athletes seeking muscle hypertrophy | [Community] |
| subcutaneous injection | 20-40 mcg | once daily · 4-6 weeks | beginner biohackers or those cautious about side effects | [Community] |
| intramuscular injection | 100 mcg | once daily, post-workout · 4 weeks on, 4 weeks off | experienced bodybuilders and anabolic steroid users adding IGF-1 LR3 to a stack | [Community] |
| subcutaneous injection | 50 mcg | once daily · 4 weeks on, 4 weeks off | women using IGF-1 LR3 for body recomposition | [Community] |
| subcutaneous injection | 40-60 mcg | once daily · 6 weeks | biohackers and anti-aging enthusiasts seeking tissue repair and longevity | [Community] |
| subcutaneous injection | 80-120 mcg | once daily, post-workout · 4 weeks | advanced performance athletes and competitive bodybuilders | [Community] |
| subcutaneous injection | 50-100 mcg | once daily · 4-6 weeks | post-injury athletes and individuals recovering from soft-tissue damage | [Community] |
| subcutaneous injection | 100 mcg | once daily, post-workout on training days only · 4 weeks | bodybuilders running an anabolic steroid or SARMs cycle | [Community] |
Blends containing this peptide
All studies (32)
- PMID 11334915 Mixed
Ovarian follicle and granulosa/theca cell research (in vitro and animal model) - PMID 17636166 Mixed
Ovarian follicle and granulosa/theca cell research (in vitro and animal model) - PMID 7683875 Animal studies only
Restoration of growth in diabetic rats (animal model) - PMID 8053901 Animal studies only
Tumour-bearing rat metabolism and muscle protein accretion (animal model) - PMID 8691093
- PMID 9538331
1–100 µg/L LR3-IGF-I In vitro culture medium supplementation (in_vitro) - PMID 10198302
- PMID 10226789 Animal studies only
Small intestinal cell growth (animal model) - PMID 10855689
LR3-IGF-I (dose not specified in abstract) In vivo infusion (pump) (animal) - PMID 11181549
100 ng/ml In vitro culture medium supplementation (in_vitro) - PMID 11485445
- PMID 11524236
LR3-IGF-I (dose not specified in abstract) In vivo infusion (pump), then in vitro culture (animal) - PMID 12067429 Animal studies only
Growth promotion in neonatal pigs (animal model) - PMID 12947030 Animal studies only
Cardiac growth and cardiomyocyte proliferation (animal model) - PMID 16166219
LR3-IGF-I injection (dose not specified in abstract) Injection (route not specified in abstract) (animal) - PMID 18577570 Animal studies only
Lactation enhancement in mice (animal model) - PMID 19633297 In vitro only
IGF-1 receptor signalling studies / research tool use - PMID 22227200 In vitro only
Rumen epithelial sodium transport (animal/in vitro model) - PMID 25154301
100 ng/ml LR3-IGF-1 In vitro culture medium supplementation (in_vitro) - PMID 26166219
LR3-IGF-I at 1–100 µg/L (analogue in serum-free culture) In vitro culture medium supplementation (in_vitro) - PMID 31285507 Animal studies only
Cancer cachexia / muscle wasting (animal and in vitro model) - PMID 32573852 Animal studies only
Cardiac growth and cardiomyocyte proliferation (animal model) - PMID 33427051 Animal studies only
Fetal growth and organ development (animal model) - PMID 33938236 Animal studies only
Attenuation of glucose-stimulated insulin secretion in fetal sheep (animal model) - PMID 36091374 Animal studies only
Fetal growth and organ development (animal model) - PMID 36499281 In vitro only
IGF-1 receptor signalling studies / research tool use - PMID 37114757 Animal studies only
Attenuation of glucose-stimulated insulin secretion in fetal sheep (animal model) - PMID 39610283 Animal studies only
Alzheimer's disease / amyloid pathology (animal model) - PMID 39679943 Animal studies only
Fetal growth and organ development (animal model) - PMID 41015370 Animal studies only
Peripheral nerve regeneration (animal model) - PMID 41418663 Animal studies only
Volumetric muscle loss repair (animal model) - PMID 42395176
Adverse effects of GH-IGF-1 axis peptides in self-administration contexts reported in a narrative review to include endocrine and metabolic disturbances (prolac